Literature DB >> 25459126

Pathophysiology and biomarkers in chronic inflammatory demyelinating polyradiculoneuropathies.

J Svahn1, J-C Antoine2, J-P Camdessanché3.   

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired dysimmune disorder characterized by strong heterogeneity in terms of clinical manifestations, prognostic and response to treatment. To date, its pathophysiology and potential target antigens are not totally identified despite substantial progress in the understanding of the involved molecular mechanisms. Recent researches in the field have underlined the importance of cell-mediated immunity (lymphocytesT CD4+, CD8+ and macrophages), the breakdown of blood-nerve barrier, a failure of T-cell regulation, and the disruption of nodal and paranodal organization at the node of Ranvier. This last point is possibly mediated by autoantibodies towards axoglial adhesion molecules which may disrupt sodium and potassium voltage-gated channels clustering leading to a failure of saltatory conduction and the apparition of conduction blocks. The purpose of this article is to overview the main pathophysiologic mechanisms and biomarkers identified in CIDP.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Biomarkers; Biomarqueurs; Chronic inflammatory demyelinating polyradiculoneuropathy; Dysimmunity; Dysimmunité; Nodo-paranodopathies; Pathophysiology; Physiopathologie; Polyradiculoneuropathie inflammatoire démyélinisante chronique

Mesh:

Substances:

Year:  2014        PMID: 25459126     DOI: 10.1016/j.neurol.2014.10.009

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  2 in total

Review 1.  The macrophage: a key player in the pathophysiology of peripheral neuropathies.

Authors:  Zeina Msheik; Mohamed El Massry; Amandine Rovini; Fabrice Billet; Alexis Desmoulière
Journal:  J Neuroinflammation       Date:  2022-04-16       Impact factor: 9.587

2.  Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio.

Authors:  Gurmukh Singh
Journal:  J Clin Med Res       Date:  2016-11-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.